
M. Franco G. Salvoza
Examiner (ID: 9168)
| Most Active Art Unit | 1648 |
| Art Unit(s) | 1671, 1648, 1672 |
| Total Applications | 797 |
| Issued Applications | 453 |
| Pending Applications | 121 |
| Abandoned Applications | 245 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 17291011
[patent_doc_number] => 20210386850
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-12-16
[patent_title] => FUSION PROTEIN
[patent_app_type] => utility
[patent_app_number] => 17/285786
[patent_app_country] => US
[patent_app_date] => 2019-10-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16819
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17285786
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/285786 | FUSION PROTEIN | Oct 15, 2019 | Abandoned |
Array
(
[id] => 17527885
[patent_doc_number] => 11300565
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-04-12
[patent_title] => Exosome-mediated diagnosis of human immunodeficiency virus infection
[patent_app_type] => utility
[patent_app_number] => 16/601178
[patent_app_country] => US
[patent_app_date] => 2019-10-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 11
[patent_figures_cnt] => 27
[patent_no_of_words] => 14552
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 154
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16601178
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/601178 | Exosome-mediated diagnosis of human immunodeficiency virus infection | Oct 13, 2019 | Issued |
Array
(
[id] => 17163167
[patent_doc_number] => 11149256
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-10-19
[patent_title] => Adeno-associated virus compositions for targeted gene therapy
[patent_app_type] => utility
[patent_app_number] => 16/582635
[patent_app_country] => US
[patent_app_date] => 2019-09-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 211
[patent_figures_cnt] => 50
[patent_no_of_words] => 56853
[patent_no_of_claims] => 25
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 103
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16582635
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/582635 | Adeno-associated virus compositions for targeted gene therapy | Sep 24, 2019 | Issued |
Array
(
[id] => 15345237
[patent_doc_number] => 20200010510
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-01-09
[patent_title] => RECOMBINANT AAV1, AAV5, AND AAV6 CAPSID MUTANTS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 16/565191
[patent_app_country] => US
[patent_app_date] => 2019-09-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14968
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 97
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16565191
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/565191 | Recombinant AAV1, AAV5, and AAV6 capsid mutants and uses thereof | Sep 8, 2019 | Issued |
Array
(
[id] => 15290801
[patent_doc_number] => 20190388536
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-12-26
[patent_title] => Human Type 14 Replication Defective Adenovirus Vector and Preparation Method for Same and Applications Thereof
[patent_app_type] => utility
[patent_app_number] => 16/558301
[patent_app_country] => US
[patent_app_date] => 2019-09-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7658
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 58
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16558301
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/558301 | Human Type 14 Replication Defective Adenovirus Vector and Preparation Method for Same and Applications Thereof | Sep 1, 2019 | Abandoned |
Array
(
[id] => 15646827
[patent_doc_number] => 20200085943
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-03-19
[patent_title] => PHARMACEUTICAL COMPOSITION COMPRISING A POLYMERIC CARRIER CARGO COMPLEX AND AT LEAST ONE PROTEIN OR PEPTIDE ANTIGEN
[patent_app_type] => utility
[patent_app_number] => 16/555881
[patent_app_country] => US
[patent_app_date] => 2019-08-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 78883
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16555881
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/555881 | Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen | Aug 28, 2019 | Issued |
Array
(
[id] => 16176958
[patent_doc_number] => 20200223926
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-07-16
[patent_title] => COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFECTIONS AND TUMORS
[patent_app_type] => utility
[patent_app_number] => 16/550115
[patent_app_country] => US
[patent_app_date] => 2019-08-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 46905
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 45
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16550115
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/550115 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFECTIONS AND TUMORS | Aug 22, 2019 | Abandoned |
Array
(
[id] => 16204902
[patent_doc_number] => 20200237892
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-07-30
[patent_title] => FLAVIVIRUS PEPTIDE SEQUENCES, EPITOPES, AND METHODS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 16/537447
[patent_app_country] => US
[patent_app_date] => 2019-08-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 44234
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16537447
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/537447 | Flavivirus peptide sequences, epitopes, and methods and uses thereof | Aug 8, 2019 | Issued |
Array
(
[id] => 15960345
[patent_doc_number] => 20200163924
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-05-28
[patent_title] => COMPOSITIONS AND METHODS FOR REACTIVATING LATENT VIRAL INFECTIONS
[patent_app_type] => utility
[patent_app_number] => 16/506841
[patent_app_country] => US
[patent_app_date] => 2019-07-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 24294
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16506841
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/506841 | COMPOSITIONS AND METHODS FOR REACTIVATING LATENT VIRAL INFECTIONS | Jul 8, 2019 | Abandoned |
Array
(
[id] => 15294081
[patent_doc_number] => 20190390176
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-12-26
[patent_title] => NOVEL RECOMBINANT ADENO-ASSOCIATED VIRUS CAPSIDS WITH ENHANCED HUMAN SKELETAL MUSCLE TROPISM
[patent_app_type] => utility
[patent_app_number] => 16/503293
[patent_app_country] => US
[patent_app_date] => 2019-07-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 39083
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16503293
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/503293 | NOVEL RECOMBINANT ADENO-ASSOCIATED VIRUS CAPSIDS WITH ENHANCED HUMAN SKELETAL MUSCLE TROPISM | Jul 2, 2019 | Abandoned |
Array
(
[id] => 16176939
[patent_doc_number] => 20200223907
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-07-16
[patent_title] => ANTIBODIES THAT TARGET HIV GP120 AND METHODS OF USE
[patent_app_type] => utility
[patent_app_number] => 16/460094
[patent_app_country] => US
[patent_app_date] => 2019-07-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 66321
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -63
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16460094
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/460094 | Antibodies that target HIV GP120 and methods of use | Jul 1, 2019 | Issued |
Array
(
[id] => 17666405
[patent_doc_number] => 11360090
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-06-14
[patent_title] => Exosome-mediated diagnosis of hepatitis virus infections and diseases
[patent_app_type] => utility
[patent_app_number] => 16/455807
[patent_app_country] => US
[patent_app_date] => 2019-06-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 11
[patent_figures_cnt] => 27
[patent_no_of_words] => 14491
[patent_no_of_claims] => 7
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 122
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16455807
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/455807 | Exosome-mediated diagnosis of hepatitis virus infections and diseases | Jun 27, 2019 | Issued |
Array
(
[id] => 16744329
[patent_doc_number] => 10969309
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-04-06
[patent_title] => Virus concentration method
[patent_app_type] => utility
[patent_app_number] => 16/451824
[patent_app_country] => US
[patent_app_date] => 2019-06-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4555
[patent_no_of_claims] => 5
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 56
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16451824
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/451824 | Virus concentration method | Jun 24, 2019 | Issued |
Array
(
[id] => 17103233
[patent_doc_number] => 11123424
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-09-21
[patent_title] => Baculovirus and composition for detection and preventing of porcine epidemic diarrhea virus infection
[patent_app_type] => utility
[patent_app_number] => 16/450810
[patent_app_country] => US
[patent_app_date] => 2019-06-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 10
[patent_figures_cnt] => 14
[patent_no_of_words] => 7231
[patent_no_of_claims] => 8
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 22
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16450810
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/450810 | Baculovirus and composition for detection and preventing of porcine epidemic diarrhea virus infection | Jun 23, 2019 | Issued |
Array
(
[id] => 17035174
[patent_doc_number] => 20210252132
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-08-19
[patent_title] => COMPOSITION AND METHOD FOR STABILISING VACCINES IN A SOLID DOSAGE FORMAT
[patent_app_type] => utility
[patent_app_number] => 17/251965
[patent_app_country] => US
[patent_app_date] => 2019-06-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7663
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -33
[patent_words_short_claim] => 49
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17251965
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/251965 | COMPOSITION AND METHOD FOR STABILISING VACCINES IN A SOLID DOSAGE FORMAT | Jun 11, 2019 | Abandoned |
Array
(
[id] => 15020913
[patent_doc_number] => 20190321461
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-10-24
[patent_title] => ENGINEERED AND MULTIMERIZED HUMAN IMMUNODEFICIENCY VIRUS ENVELOPE GLYCOPROTEINS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 16/430172
[patent_app_country] => US
[patent_app_date] => 2019-06-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19900
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -22
[patent_words_short_claim] => 13
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16430172
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/430172 | Engineered and multimerized human immunodeficiency virus envelope glycoproteins and uses thereof | Jun 2, 2019 | Issued |
Array
(
[id] => 18436445
[patent_doc_number] => 20230183739
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-15
[patent_title] => RECOMBINANT MEASLES VIRUS EXPRESSING PROTEINS OF A PLASMODIUM PARASITE AND THEIR APPLICATIONS
[patent_app_type] => utility
[patent_app_number] => 17/057235
[patent_app_country] => US
[patent_app_date] => 2019-05-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18254
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -27
[patent_words_short_claim] => 313
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17057235
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/057235 | RECOMBINANT MEASLES VIRUS EXPRESSING PROTEINS OF A PLASMODIUM PARASITE AND THEIR APPLICATIONS | May 22, 2019 | Abandoned |
Array
(
[id] => 14833473
[patent_doc_number] => 20190275137
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-09-12
[patent_title] => Immunogenic Influenza Composition
[patent_app_type] => utility
[patent_app_number] => 16/420192
[patent_app_country] => US
[patent_app_date] => 2019-05-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13827
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16420192
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/420192 | Immunogenic Influenza Composition | May 22, 2019 | Abandoned |
Array
(
[id] => 15649645
[patent_doc_number] => 20200087352
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-03-19
[patent_title] => ASSEMBLY ACTIVATING PROTEIN (AAP) AND ITS USE FOR THE MANUFACTURE OF PARVOVIRUS PARTICLES ESSENTIALLY CONSISTING OF VP3
[patent_app_type] => utility
[patent_app_number] => 16/415676
[patent_app_country] => US
[patent_app_date] => 2019-05-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 36611
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16415676
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/415676 | Assembly activating protein (AAP) and its use for the manufacture of parvovirus particles essentially consisting of VP3 | May 16, 2019 | Issued |
Array
(
[id] => 14899767
[patent_doc_number] => 20190293649
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-09-26
[patent_title] => Proteome Editing System
[patent_app_type] => utility
[patent_app_number] => 16/413282
[patent_app_country] => US
[patent_app_date] => 2019-05-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11921
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -5
[patent_words_short_claim] => 54
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16413282
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/413282 | Proteome Editing System | May 14, 2019 | Abandoned |